Takeda https://www.takeda.com/closed the agreement to sell its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma, the Chinese company specialised in the research, discovery and marketing of urinary protein biopharmaceuticals and production of biopharmaceuticals in critical care. The shareholding is to be acquired in an all-cash by Takeda’s joint venture partner in Techpool: Shanghai Pharmaceutical Holding Co. Ltd. and a fund managed by SFund International Investment Fund Management Limited.